Publications by authors named "Michael A Bookman"

Claim this Profile
C
Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.
Yvette Drew, Michael A Bookman

JAMA Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael A Bookman

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay, Michael A Bookman

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Jubilee Brown, Austin Miller, Laura L Holman, Floor Backes, Christa Nagel, Michael A Bookman

Gynecol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.
Jalid Sehouli, Jolijn Boer, Alison H Brand, Amit M Oza, Jennifer O'Donnell, Michael A Bookman

Int J Gynecol Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Carien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, Emma Allanson, Lauriane Eberst, Michael A Bookman

Lancet Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Michael A Bookman

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Tiffany Y Sia, William P Tew, Christopher Purdy, Dennis S Chi, Andrew W Menzin, Michael A Bookman

Gynecol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J Ansell, Michael A Bookman

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Michael A Bookman

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, Michael A Bookman

J Clin Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Junsik Park, Se Ik Kim, Soo Young Jeong, Yup Kim, Michael A Bookman

Gynecol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Elizabeth M Swisher, Carol Aghajanian, David M O'Malley, Gini F Fleming, Scott H Kaufmann, Michael A Bookman

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Carol Aghajanian, Elizabeth M Swisher, Aikou Okamoto, Karina Dahl Steffensen, Michael A Bookman

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Katherine C Fuh, Michael A Bookman, Joyce F Liu, Robert L Coleman, Thomas J Herzog

Gynecol Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Carol Aghajanian, Michael A Bookman, Gini F Fleming, Elizabeth M Swisher, Karina D Steffensen

Gynecol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer.
Edward H Williams, Thomas R Flint, Claire M Connell, Daniel Giglio, Hassal Lee, Michael A Bookman

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael A Bookman

N Engl J Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate.
Edward H Williams, Claire M Connell, James M J Weaver, Ian Beh, Harry Potts, Michael A Bookman

JNCI Cancer Spectr· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we predict who lives long with ovarian cancer?
Michael A Bookman

Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Ignace Vergote, Robert L Coleman, Sandro Pignata, Michael A Bookman, Christian Marth

Int J Gynecol Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.
Charlie Gourley, Michael A Bookman

J Clin Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Katherine C Fuh, James J Java, John K Chan, Daniel S Kapp, Bradley J Monk, Michael A Bookman

Gynecol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Ignace Vergote, Robert L Coleman, Sandro Pignata, Michael A Bookman, Christian Marth

Gynecol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis